NZ546440A - Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds - Google Patents

Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds

Info

Publication number
NZ546440A
NZ546440A NZ546440A NZ54644004A NZ546440A NZ 546440 A NZ546440 A NZ 546440A NZ 546440 A NZ546440 A NZ 546440A NZ 54644004 A NZ54644004 A NZ 54644004A NZ 546440 A NZ546440 A NZ 546440A
Authority
NZ
New Zealand
Prior art keywords
methylene
dihydroxyvitamin
dihydroxy
dehydrovitamin
trihomo
Prior art date
Application number
NZ546440A
Other languages
English (en)
Inventor
Hector F Deluca
Margherita Cantorna
Original Assignee
Wisconsin Alumni Res Found
Penn State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found, Penn State Res Found filed Critical Wisconsin Alumni Res Found
Publication of NZ546440A publication Critical patent/NZ546440A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ546440A 2003-10-08 2004-07-23 Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds NZ546440A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/680,881 US7704980B2 (en) 2003-10-08 2003-10-08 Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
PCT/US2004/023586 WO2005039592A1 (en) 2003-10-08 2004-07-23 Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin d compounds

Publications (1)

Publication Number Publication Date
NZ546440A true NZ546440A (en) 2009-08-28

Family

ID=34422197

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ546440A NZ546440A (en) 2003-10-08 2004-07-23 Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds

Country Status (10)

Country Link
US (2) US7704980B2 (enExample)
EP (1) EP1673095B1 (enExample)
JP (1) JP2007508298A (enExample)
AT (1) ATE448788T1 (enExample)
AU (1) AU2004283073B2 (enExample)
CA (1) CA2541991A1 (enExample)
DE (1) DE602004024221D1 (enExample)
ES (1) ES2338428T3 (enExample)
NZ (1) NZ546440A (enExample)
WO (1) WO2005039592A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2764577C (en) * 2009-08-03 2017-12-19 Wisconsin Alumni Research Foundation Method of preventing renal disease and treating symptoms thereof
US20110237557A1 (en) * 2010-03-23 2011-09-29 Deluca Hector F Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3
US8604009B2 (en) * 2010-03-23 2013-12-10 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
FR2961401B1 (fr) * 2010-06-17 2013-04-05 Laetitia Mathez Composition anti-inflammatoire
CN102631354B (zh) * 2011-02-11 2015-01-21 广东泰禾医药科技有限公司 含维生素d3和二甲双胍的药物组合物
WO2012166938A2 (en) 2011-06-03 2012-12-06 Wisconsin Alumni Research Foundation (22e)-2-methylene-26,27-cyclo-22-dehydro-1alpha-hydroxy-19-norvitamin d3 derivatives
US20130295083A1 (en) * 2012-05-02 2013-11-07 Wisconsin Alumni Research Foundation 2a-Methyl-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2AMD) or 2 methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2MD) Support Survival and Function of Transplanted Islet Cells In Type 1 Diabetes
HK1206600A1 (en) 2012-06-29 2016-01-15 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM
US9370527B2 (en) 2012-12-28 2016-06-21 The Regents Of The University Of Michigan Amelioration of intestinal fibrosis and treatment of Crohn's disease
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
WO2017184262A1 (en) * 2016-04-18 2017-10-26 Wisconsin Alumni Research Foundation Use of 2amd and 2md to treat fibrosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4221961A1 (de) 1992-06-30 1994-01-05 Schering Ag 22-En-25-oxa-Derivate in der Vitamin D-Reihe, Verfahren zu ihrer Herstellung, diese Derivate enthaltenen pharmazeutische Präparate sowie deren Verwendung als Arzneimittel
IL107185A (en) 1992-10-06 1998-02-22 Schering Ag Vitamin d, 25-carboxylic acid derivatives and pharmaceutical compositions containing the same
US5981597A (en) * 1995-02-13 1999-11-09 Trustees Of The University Of Pennsylvania Differentiating agents for the treatment of inflammatory intestinal diseases
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US6358939B1 (en) * 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) * 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US6806262B2 (en) * 2000-05-31 2004-10-19 Wisconsin Alumni Research Foundation 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds
AU7544501A (en) * 2000-09-08 2002-03-22 Wisconsin Alumni Res Found 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
WO2003051828A2 (en) * 2001-12-13 2003-06-26 Wisconsin Alumni Research Foundation (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
US7259143B2 (en) * 2002-09-05 2007-08-21 Wisconsin Alumni Research Foundation Method of extending the dose range of vitamin D compounds

Also Published As

Publication number Publication date
DE602004024221D1 (de) 2009-12-31
AU2004283073A1 (en) 2005-05-06
ES2338428T3 (es) 2010-05-07
US20100160267A1 (en) 2010-06-24
ATE448788T1 (de) 2009-12-15
EP1673095B1 (en) 2009-11-18
EP1673095A1 (en) 2006-06-28
JP2007508298A (ja) 2007-04-05
WO2005039592A1 (en) 2005-05-06
US7704980B2 (en) 2010-04-27
US20050080059A1 (en) 2005-04-14
CA2541991A1 (en) 2005-05-06
AU2004283073B2 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
GB0225475D0 (en) Therapeutic agents
GB0318447D0 (en) Therapeutic agents
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
PL1656372T3 (pl) Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
WO2004006858A3 (en) Compounds, compositions, and methods employing same
PT2527315E (pt) Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
MY127290A (en) New use of flibanserin
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
NZ546440A (en) Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
GB0223038D0 (en) Therapeutic compounds
PT1594833E (pt) Derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
UA83691C2 (ru) Применение замещенных 2-аминотетралинов для упреждающего лечения болезни паркинсона
EP1830191A3 (en) Pharmaceutical preparations containing thiazolidinediones for the treatment of endocrine autoimmune diseases
WO2003087049A3 (de) Arzneimittelkombinationen enthaltend heterocyclische verbindungen und ein neues anticholinergikum
MY148125A (en) Compounds
TWI340639B (en) Pharmaceutical composition for treating luts, other than urinary incontinence, associated with oab and/or bph
TW200505408A (en) Agent for preventing and/or treating tissue disruption-accompanied diseases
WO2004087880A3 (en) Compounds and their use to treat diabetes and related disorders
AU2003290015A1 (en) Mastitis treatment
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
WO2005022164A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8)
WO2004097358A3 (en) Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 JUL 2017 BY CPA GLOBAL

Effective date: 20140605

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUL 2018 BY CPA GLOBAL

Effective date: 20170608

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUL 2019 BY CPA GLOBAL

Effective date: 20180607

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUL 2020 BY CPA GLOBAL

Effective date: 20190606

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUL 2021 BY CPA GLOBAL

Effective date: 20200611

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUL 2022 BY CPA GLOBAL

Effective date: 20210610

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUL 2023 BY CPA GLOBAL

Effective date: 20220609

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUL 2024 BY CPA GLOBAL

Effective date: 20230608

EXPY Patent expired